Evidence map›Paper›PMID 27072961›Full record

ArticleJournal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban2016

Over-expression of Sox4 and β-catenin is associated with a less favorable prognosis of osteosarcoma.

Zheng-Qi Bao, Chang-Chun Zhang, Yu-Zhou Xiao, Jian-Sheng Zhou, Yi-Sheng Tao, Da-Min Chai

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Expression of β-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zheng-Qi BaoDepartment of Orthopaedics, the First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Chang-Chun ZhangDepartment of Orthopaedics, the First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Yu-Zhou XiaoDepartment of Orthopaedics, the First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Jian-Sheng ZhouDepartment of Orthopaedics, the First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Yi-Sheng TaoDepartment of Pathology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Da-Min ChaiDepartment of Pathology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China. msautumn@163.com.
First Affiliated Hospital of Bengbu Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to examine the association of the expression of Sox4 and β-catenin with the prognosis of osteosarcoma. A total of 108 cases of conventional osteosarcoma were involved in this study and 28 cases of osteochondroma served as controls. The expression of Sox4 and β-catenin was detected by using immunohistochemical staining and Western blotting. The results showed that Sox4 and β-catenin were over-expressed in 67 (62.03%) and 62 (57.41%) of 108 osteosarcoma cases, while in only 3 (10.71%) and 5 (17.86%) of 28 controls, respectively (P<0.05 for all). The expression of Sox4 and β-catenin was associated with the distant metastasis, pathological grade and Enneking stage of patients with osteosarcoma (P<0.05 for all). The mean overall survival time and the 5-year-survival rate in osteosarcoma patients with Sox4 and β-catenin over-expressed were significantly reduced as compared with those in Sox4 and β-catenin low-expression group (P<0.05 for all). Cox multifactor regression analysis revealed that the distant metastasis, Enneking stage, and the expression of Sox4 and β-catenin were independent risk factors of patients with osteosarcoma (P<0.05 for all). The findings indicated that overexpression of Sox4 and β-catenin is associated with a poor prognosis of osteosarcoma.

Indexed as

AdolescentAdultbeta CateninBiomarkers, TumorBone NeoplasmsCase-Control StudiesChildFemaleHumansLung NeoplasmsMaleMiddle AgedOsteosarcomaSOXC Transcription Factorsbeta CateninBiomarkers, TumorSOX4 protein, humanSOXC Transcription FactorsosteochondromaosteosarcomaprognosisSox4β-catenin

Identifiers

PMID27072961
OpenAlexW2339986619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.